Novel VEGFR-2 inhibitors with an N-acylhydrazone scaffold

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Vascular endothelial growth factor receptor 2 (VEGFR-2) is a key tyrosine kinase in angiogenesis.
• Inhibiting VEGFR-2 is a promising strategy for controlling solid tumor growth.
• Angiogenesis plays a critical role in tumorigenesis.

Purpose of the Study:

• To design, synthesize, and biologically evaluate novel N-acylhydrazone (NAH) scaffold-based VEGFR-2 inhibitors.
• To explore the potential of these compounds as anti-angiogenic agents.

Main Methods:

• Synthesis of a novel series of N-acylhydrazone (NAH) derivatives (compounds 9a-h).
• Molecular docking studies to validate inhibitor design.
• In vitro inhibitory activity assays and chorioallantoic membrane assay for neovascularization inhibition.

Main Results:

• Molecular design was validated through docking and in vitro assays.
• Compounds 9b, 9c, 9d, and 9f demonstrated significant inhibition of VEGF-induced neovascularization.
• These compounds effectively inhibited angiogenesis in the chorioallantoic membrane assay.

Conclusions:

• The synthesized N-acylhydrazone derivatives are effective inhibitors of VEGFR-2.
• Compounds 9b, 9c, 9d, and 9f show potent anti-angiogenic activity.
• These NAH derivatives represent promising prototypes for developing novel anti-cancer therapeutics.